Decitabine treatment of patients with higher-risk myelodysplastic syndromes

被引：15
作者：
Steensma, David P. [1 ]
机构：
[1] Dana Farber Canc Inst, Dept Hematol Malignancies, Boston, MA 02115 USA
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷
关键词：
Myelodysplastic syndromes; Clinical trials; DNA methylation; Decitabine; 5-Aza-2 '-deoxycytidine; Azacitidine; CHRONIC-MYELOMONOCYTIC-LEUKEMIA; INTERNATIONAL WORKING GROUP; RESPONSE CRITERIA; CLINICAL-RESPONSE; PHASE-III; AZACITIDINE; MONOSOMY-7; EFFICACY; CANCER; TRIAL;
D O I：
10.1016/S0145-2126(09)70228-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Since receiving US regulatory approval in 2006 for the treatment of patients with myelodysplastic syndromes, decitabine has also gained marketing approval in several other countries. Rates of complete remission (CR) reported for decitabine range from 9% in the US registration trial to 34% in a study of novel treatment schedules, while reported overall improvement rates range from 30% to 73%. Further studies are needed to determine the relative merits of decitabine compared with azacitidine, the optimal decitabine dose and schedule, how best to proceed following CR, molecular predictors of treatment response, and the possible role of this agent in combination regimens. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码：S12 / S17
页数：6
相关论文
共 50 条
  • [31] Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
    Bell, Jill A.
    Galaznik, Aaron
    Huelin, Rachel
    Stokes, Michael
    Guo, Yelan
    Fram, Robert J.
    Faller, Douglas V.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (04) : E157 - E166
  • [32] Oral Clofarabine in the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome
    Faderl, Stefan
    Garcia-Manero, Guillermo
    Estrov, Zeev
    Ravandi, Farhad
    Borthakur, Gautam
    Cortes, Jorge E.
    O'Brien, Susan
    Gandhi, Varsha
    Plunkett, William
    Byrd, Anna
    Kwari, Monica
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) : 2755 - 2760
  • [33] Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes
    Caocci, G.
    Voso, M. T.
    Angelucci, E.
    Stauder, R.
    Cottone, F.
    Abel, G.
    Nguyen, K.
    Platzbecker, U.
    Beyne-Rauzy, O.
    Gaidano, G.
    Invernizzi, R.
    Molica, S.
    Criscuolo, M.
    Breccia, M.
    Luebbert, M.
    Sanpaolo, G.
    Buccisano, F.
    Ricco, A.
    Palumbo, G. A.
    Niscola, P.
    Zhang, H.
    Fenu, S.
    La Nasa, G.
    Mandelli, F.
    Efficace, F.
    LEUKEMIA RESEARCH, 2015, 39 (08) : 859 - 865
  • [34] Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes
    Papadopoulos, Vasileios
    Diamantopoulos, Panagiotis T.
    Papageorgiou, Sotirios G.
    Papoutselis, Menelaos
    Vrachiolias, George
    Pappa, Vassiliki
    Galanopoulos, Athanasios G.
    Vassilakopoulos, Theodoros P.
    Hatzimichael, Eleftheria
    Zikos, Panagiotis
    Papadaki, Helen A.
    Bouchla, Anthi
    Panayiotidis, Panayiotis
    Megalakaki, Aekaterini
    Papaioannou, Maria
    Liapis, Konstantinos
    Dryllis, George
    Tsokanas, Dimitris
    Kourakli, Alexandra
    Symeonidis, Argiris
    Viniou, Nora-Athina
    Kotsianidis, Ioannis
    HEMATOLOGICAL ONCOLOGY, 2020, 38 (04) : 541 - 553
  • [35] A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia
    Santini, V.
    Allione, B.
    Zini, G.
    Gioia, D.
    Lunghi, M.
    Poloni, A.
    Cilloni, D.
    Sanna, A.
    Masiera, E.
    Ceccarelli, M.
    Abdel-Wahab, O.
    Terenzi, A.
    Angelucci, E.
    Finelli, C.
    Onida, F.
    Pelizzari, A.
    Ferrero, D.
    Saglio, G.
    Figueroa, M.
    Levis, A.
    LEUKEMIA, 2018, 32 (02) : 413 - 418
  • [36] Continued Azacitidine Therapy Beyond Time of First Response Improves Quality of Response in Patients With Higher-Risk Myelodysplastic Syndromes
    Silverman, Lewis R.
    Fenaux, Pierre
    Mufti, Ghulam J.
    Santini, Valeria
    Hellstrom-Lindberg, Eva
    Gattermann, Norbert
    Sanz, Guillermo
    List, Alan F.
    Gore, Steven D.
    Seymour, John F.
    CANCER, 2011, 117 (12) : 2697 - 2702
  • [37] Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
    Sallman, David A.
    Al Malki, Monzr M.
    Asch, Adam S.
    Wang, Eunice S.
    Jurcic, Joseph G.
    Bradley, Terrence J.
    Flinn, Ian W.
    Pollyea, Daniel A.
    Kambhampati, Suman
    Tanaka, Tiffany N.
    Zeidner, Joshua F.
    Garcia-Manero, Guillermo
    Jeyakumar, Deepa
    Komrokji, Rami
    Lancet, Jeffrey
    Kantarjian, Hagop M.
    Gu, Lin
    Zhang, Yajia
    Tan, Anderson
    Chao, Mark
    O'Hear, Carol
    Ramsingh, Giridharan
    Lal, Indu
    Vyas, Paresh
    Daver, Naval G.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (15) : 2815 - +
  • [38] A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia
    Zeidan, Amer M.
    Smith, B. Douglas
    Carraway, Hetty E.
    Gojo, Ivana
    DeZern, Amy
    Gore, Steven D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (02) : 241 - 247
  • [39] Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
    Itzykson, Raphael
    Thepot, Sylvain
    Quesnel, Bruno
    Dreyfus, Francois
    Beyne-Rauzy, Odile
    Turlure, Pascal
    Vey, Norbert
    Recher, Christian
    Dartigeas, Caroline
    Legros, Laurence
    Delaunay, Jacques
    Salanoubat, Celia
    Visanica, Sorin
    Stamatoullas, Aspasia
    Isnard, Francoise
    Marfaing-Koka, Anne
    de Botton, Stephane
    Chelghoum, Youcef
    Taksin, Anne-Laure
    Plantier, Isabelle
    Ame, Shanti
    Boehrer, Simone
    Gardin, Claude
    Beach, C. L.
    Ades, Lionel
    Fenaux, Pierre
    BLOOD, 2011, 117 (02) : 403 - 411
  • [40] Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes
    Seymour, John F.
    Bennett, John M.
    List, Alan F.
    Mufti, Ghulam J.
    Gore, Steven D.
    Fenaux, Pierre
    Santini, Valeria
    Hetzer, Joel
    Songer, Stephen
    Skikne, Barry S.
    Beach, Charles L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (01) : 49 - 56
12345